Rapamycin Nanoparticles Rejuvenate Aging Spine Discs by Silencing a Cellular Aging Switch

Back pain driven by degenerating spinal discs afflicts hundreds of millions of people worldwide, yet treatment options have barely moved beyond painkillers and surgery. Now, a research team writing in Bioengineering & Translational Medicine reports a potentially transformative approach: rapamycin, the well-known laboratory longevity drug, packaged inside nanoscale fat bubbles and delivered directly into damaged discs, where it appears to stop the resident cells from sliding into a senescent, inflammation-spewing state. In rats, the treatment measurably slowed disc degeneration over a month of follow-up, raising the tantalizing prospect of an injectable therapy that targets the biology of disc aging rather than merely its symptoms.

The scientific logic centers on a cellular decision point. Nucleus pulposus cells, the gel-cored disc’s key residents, live in a sealed, blood-starved microenvironment and normally sit quietly in the G0 phase of the cell cycle, a reversible resting state called quiescence. The researchers emphasize that quiescence is not simply non-proliferation; it is a youthful, senescence-free dormancy. When chronic inflammation invades the disc, however, these cells can tip from healthy quiescence into senescence, an irreversible arrest in which they enlarge, flatten, accumulate senescence-associated beta-galactosidase, and begin pumping out inflammatory molecules such as interleukin-1 beta and tumor necrosis factor-alpha. Those secreted factors then corrode the disc’s extracellular matrix and can even push neighboring healthy cells into senescence, creating a vicious degenerative loop.

At the hub of this decision sits mTORC1, the mechanistic target of rapamycin complex 1, a master regulator that determines whether a cell exiting the cell cycle enters quiescence or senescence. Elevated mTORC1 phosphorylation drives growth arrest, autophagy-lysosome dysfunction, and inflammatory signaling. The team hypothesized that inhibiting mTORC1 with rapamycin would do two things at once: reactivate the autophagy-lysosomal pathway, the cellular waste-disposal system that engulfs damaged molecules and organelles, and suppress the NLRP3/Caspase-1 inflammasome pathway, the molecular machine that matures pro-inflammatory interleukin-1 beta. In essence, the drug would simultaneously clean house and quiet the cell’s inflammatory alarms.

There was a catch. Rapamycin is stubbornly insoluble in water and has a short half-life in the body, both serious obstacles for a drug that must survive inside a disc with almost no blood supply. The researchers’ solution was to wrap it in nanoliposomes, spherical vesicles built from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine and the protective sugar trehalose. Using ultrasonic dispersion, thin-film dispersion, and filtration, they produced uniform particles measuring roughly 141 to 165 nanometers with a positive surface charge. The formulation achieved an encapsulation efficiency of about 80.4 percent and a drug loading rate of about 5 percent, figures comparable to or better than similar systems reported by other groups, and critically, it released rapamycin in a sustained fashion over 28 days in vitro.

With the delivery vehicle in hand, the team turned to rat nucleus pulposus cells cultured in low serum, a condition that mimics the nutrient-poor disc interior and keeps the cells quiescent. When they flooded this culture with interleukin-1 beta, the cells transformed: they enlarged and flattened, secreted roughly eight times more interleukin-1 beta and over twenty times more TNF-alpha than resting controls, showed far more beta-galactosidase staining, and displayed visibly wrecked lysosomes under the transmission electron microscope. Adding the rapamycin nanoliposomes substantially reversed all of these changes. Senescent cell fractions fell significantly, inflammatory cytokine secretion dropped toward baseline, and lysosomal structure and fluorescent tracer intensity moved back toward the healthy pattern, all without altering the cells’ fundamental G0/G1 cell-cycle arrest.

The molecular readouts confirmed the proposed mechanism. Western blotting and quantitative PCR showed that inflammatory stimulation raised phosphorylated mTOR, increased the inflammasome proteins NLRP3 and cleaved Caspase-1, and elevated the receptor IL-1R. It also disrupted autophagy, lowering the LC3II/LC3I ratio, a standard marker of autophagic flux, and raising P62, a cargo protein that accumulates when the disposal system jams. The nanoliposomes cut P-mTOR and the inflammasome proteins back down while restoring LC3 processing and reducing P62, exactly the signature expected if rapamycin were re-engaging the autophagy-lysosomal pathway and disarming the NLRP3/Caspase-1 cascade. Gene expression changes tracked the protein data, and blank liposomes produced no measurable effect on any marker.

To prove that mTORC1 was genuinely the target rather than an incidental bystander, the researchers silenced raptor, the defining scaffold component of mTORC1, using siRNA in the same cells. Genetic silencing reproduced the drug’s effects: phosphorylated mTOR fell, NLRP3 and Caspase-1 activation declined, P62 dropped, and the LC3II/LC3I ratio rose. The convergence of pharmacological and genetic inhibition on the same downstream pathways is the study’s strongest evidence that rapamycin nanoliposomes act through mTORC1 to coordinate the anti-aging response.

The team also dissected how the treatment distinguishes senescence from quiescence at the level of cell-cycle inhibitors. Senescent cells characteristically accumulate P16 and P21, while quiescent cells upregulate P27. Inflammatory stimulation raised P16 and P21 and suppressed P27 in the disc cells; the nanoliposomes reversed this pattern, lowering P16 and P21 while boosting P27, and raptor silencing produced the same shift. Combined with EdU incorporation assays showing that none of the treated cell populations re-entered proliferation, the data suggest the drug preserves a genuinely quiescent, non-senescent state rather than simply freezing cells wherever they happen to be.

Finally, the researchers tested the therapy in living animals by microinjecting interleukin-1 beta into rat tail discs to induce degeneration, with or without co-injection of the nanoliposomes. One month later, X-rays showed that discs receiving the inflammatory stimulus alone had lost most of their disc height, with a disc height index of about 41 percent of normal, whereas discs treated with the rapamycin nanoliposomes retained roughly 75 percent. MRI scoring by the Pfirrmann system likewise rated the treated discs significantly less degenerated than the inflamed controls, hematoxylin-eosin staining preserved visible nucleus pulposus tissue and intervertebral space, and immunofluorescence for aggrecan, a key cartilage matrix protein, showed substantially better matrix preservation in the treated group.

The authors are careful to frame the work as a translational proof of concept rather than a ready-made clinical therapy. The rat model used acute inflammatory injury rather than the slow, multifactorial degeneration seen in human patients, the follow-up period was one month, and long-term safety studies of six to twelve months of continuous administration are planned. They also note that mTORC1 regulation may not suit other aging tissues, because restraining this pathway can restrict cell metabolism, growth, and synthesis more broadly. Even so, the convergence of a simple, scalable formulation, high encapsulation efficiency, month-long sustained release, dual-pathway mechanistic validation, and structural protection in vivo marks rapamycin nanoliposomes as one of the more credible attempts yet to convert longevity biology into a targeted injection for the failing spine. If future studies confirm safety and durability, the drug that made nematode worms and mice live longer may one day be delivered straight into the discs that keep human backs moving.

Subject of Research: Rapamycin nanoliposome therapy targeting mTORC1-mediated senescence pathways in intervertebral disc degeneration

Article Title: Rapamycin‐nanoliposomes target the mTORC1‐mediated autophagy–lysosomal and NLRP3/Caspase‐1 pathways to inhibit nucleus pulposus cell senescence in intervertebral discs

Article References: Xing, H., Yu, M., Liu, J., Zhao, R., Ai, X., Tang, R., Zhu, T., Li, Y., Jiang, L., Wei, Q., Huang, Y., Guo, Y., Jiang, T., & Huang, B. (2026). Rapamycin‐nanoliposomes target the mTORC1 ‐mediated autophagy–lysosomal and NLRP3 /Caspase‐1 pathways to inhibit nucleus pulposus cell senescence in intervertebral discs. Bioengineering & Translational Medicine, Article e70165. https://doi.org/10.1002/btm2.70165

Image Credits: AI Generated

DOI: 10.1002/btm2.70165

Keywords: rapamycin, nanoliposomes, mTORC1, cell senescence, autophagy, NLRP3 inflammasome, nucleus pulposus cells, intervertebral disc degeneration, back pain, lysosomes, drug delivery, quiescence